End Stage Renal DiseaseNCT03925168
Music Therapy and Dialysis: A Pilot Investigation Into the Effectiveness of Patient-Selected Music Interventions on Physiological, Psychological, and Quality-of-Life Outcomes
A study testing Music therapy in people with End Stage Renal Disease and Depression, run by Tulane University at 3 sites in United States.
Trial summary
The objective of this study is to determine the effect of music therapy during dialysis on: depression, anxiety, quality of life, blood pressure, heart rate, medication compliance, compliance with dialysis treatment, number of hospitalizations, pain level, and energy level. Read more about this study
- Who is it for?
- Ages 21 years and older
- Conditions the study is for
- End Stage Renal Disease, Depression, Anxiety
- What is being tested?
- Music therapy
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 3 sitesUnited States
- Study dates
- 8 Mar 2019to 1 Jan 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- English-speaking, adult (21+) hemodialysis patients who receive dialysis at the one of the two outpatient dialysis centers
Who cannot join
- do not speak English, deafness
Trial locations and contacts
3 sites in 1 country.
United States3 sites
DCI Canal Street
New Orleans, Louisiana, 70112
Tulane University School of Medicine
New Orleans, Louisiana, 70112
DCI West Bank
Terrytown, Louisiana, 70056
About this study
The objective of this study is to determine the effect of music therapy during dialysis on:
depression, anxiety, quality of life, blood pressure, heart rate, medication compliance, compliance with dialysis treatment, number of hospitalizations, pain level, and energy level.
Read the detailed description
This study will be a cluster-randomized clinical trial. In order to limit contamination bias, dialysis sessions at each site will be randomized to the experimental group or the wait-list control group. For example, patients receiving MWF first-session dialysis may be randomized to the experimental group while patients receiving TTS second-session dialysis may be randomized to the control group. Due to this randomization scheme, patients will be able to receive individualized music therapy while sitting in an open dialysis unit. The subject population includes English-speaking, adult (21+) hemodialysis patients who receive dialysis at the one of the two outpatient dialysis centers included in this study. Subjects will be excluded if they do not speak English or if they are deaf as these patient populations would not be likely to benefit from music therapy administered in English. Up to 100 patients will be enrolled in this study.
Patients receiving dialysis at DCI, Inc, who consent to participate and are randomized to the experimental group will receive 30-minute music therapy sessions over the course of several months. Music therapy will be administered by certified music therapists and music therapy students according to the Eyre (2008) decision tree model. According to this model, the patient chooses his or her preferred musical intervention at the beginning of each session. Choices include: sing songs, compose a song, listen to songs, play instruments, have an imagery experience, listen to music, improvise, and use music for relaxation. If the patient is unwilling or unable to make a decision, then the music therapist will choose an intervention based on the patient's perceived needs. For example, if the perceived need is expression of emotions, then the music therapist may suggest song composition, song choice, song singing, or improvisation. The music therapist will continue to assess the client's perceived needs based on their physical, verbal, and emotional responses to the chosen musical interventions, and the therapist will adjust their musical interventions accordingly (the complete Eyre Decision Tree Model is attached). The instruments utilized in music therapy will include a classic guitar, gato box (a small, drum-like instrument), and a 3-piece egg shaker set. All of these instruments can be played loudly enough to provide music therapy to the patient but softly enough as to not disturb the adjacent patients in the dialysis unit. In fact, these instruments are frequently used to provide music therapy to patients in open neonatal intensive care units.
The primary variables in this study include depression, anxiety, and quality of life. The median time to recovery for a major depressive episode is 20 weeks; therefore, patients randomized to the control group will receive music therapy for approximately 20 weeks. Depression will be measured using the Patient Health Questionnaire-9 (PHQ-9), anxiety will be measured using the Generalized Anxiety Disorder-7 (GAD-7), and quality of life will be measured using the Kidney Disease and Quality of Life (KDQOL™-36) questionnaire. These tools are self-administered questionnaires that will be provided by the music therapists to both the experimental and control groups once a month during the study. Any patient with a PHQ-9 score greater than 10 (moderate depression) or a GAD-7 score greater than 10 (moderate anxiety) will additionally be given resources for available mental health providers in the area. While these tools are validated to be utilized every two weeks, they will be utilized every month during this study to limit testing fatigue. In addition, the PHQ-9, GAD-7, and KDQOL™-36 will be administered 30, 60, and 90 days after the experimental group receives their last music therapy session to both the experimental and control groups to assess for recurrent episodes. Among patients with major depressive disorder, recurrent episodes occur in approximately 50 percent. The risk of reoccurrence appears to be greatest in the first few months after cessation of depressive therapy.
The secondary variables in this study include blood pressure, heart rate, medication compliance, compliance with dialysis treatment, number of hospitalizations, pain level, and energy level. The music therapists will record the heart rate (HR) and blood pressure (BP) of each patient at the beginning of dialysis as well as at the beginning and end of music therapy (or a 30-minute period during which music therapy would have been administered). These HRs and BPs will be recorded using nursing vitals. Prior to the start of each session, the music therapist will provide self-administered questionnaires that ask patients to rate their pain (utilizing the Numeric Rating Scale [NRS-11]), mood, anxiety, and energy level. The patients will rate their pain, mood, anxiety, and energy level at the end of the session as well. The music therapist will record if the patient stayed for their entire treatment, or if they asked to stop dialysis early (the complete weekly and monthly data collection forms are attached). Music therapy sessions will be audio recorded using a condenser microphone and iPad Pro, and any subjective feedback from dialysis patients about music therapy sessions will be recorded as well.
- Conditions
- End Stage Renal Disease, Depression, Anxiety, Major Depressive Disorder, Generalized Anxiety Disorder, Compliance, Patient
- Being tested
- Music therapy
- Keywords
- end stage kidney disease, depression, major depressive disorder, anxiety, generalized anxiety disorder, music therapy, dialysis, quality of life, blood pressure, heart rate, pain, energy, mood, medication compliance, music
- Medical subject headings
- Kidney Failure, Chronic, Depression, Anxiety Disorders, Depressive Disorder, Major, Generalized Anxiety Disorder, Patient Compliance, Medication Adherence, Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Music therapyBehavioural
Music therapy will be administered according to the Eyre (2008) decision tree model. According to this model, the patient chooses his or her preferred musical intervention at the beginning of each session. Choices include: sing songs, compose a song, listen to songs, play instruments, have an imagery experience, listen to music, improvise, and use music for relaxation.
| Study group | Role | What they receive |
|---|---|---|
| Experimental | Experimental | Music therapy Receives: Behavioral: Music therapy |
| Control | No intervention | No music therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Depression
Measured by Patient Health Questionnaire 9 (PHQ-9). The PHQ-9 measures depression symptoms. Scores range from 0 to 27. A score of 0 to 4 indicates no depression symptoms, 5 to 9 indicates mild symptoms, 10 to 14 indicates moderate symptoms, 15 to 19 indicates moderately severe symptoms, and 20 to 27 indicates severe symptoms.
Measured: Until 90 days post study
Anxiety
Measured by Generalized Anxiety Disorder 7 patient screening tool (GAD-7). The GAD-7 measures anxiety symptoms. Scores range from 0 to 21. A score of 5 or higher indicates mild anxiety, 10 or higher indicates moderate anxiety, and 15 or higher indicates severe anxiety.
Measured: Until 90 days post study
Measuring change in Quality of life using Kidney Disease and Quality of Life 36 patient screening tool (KDQOL36)
Measured by Kidney Disease and Quality of Life 36 patient screening tool. The KDQOL36 measures quality of life for kidney disease patients. Scores range from 36 to 172. Lower scores indicate greater quality of life. Appropriate scores vary by age.
Measured: Until 90 days post study
Compliance with dialysis
Self-reported
Measured: Up to 5 months
Number of hospitalizations
Self-reported
Measured: Up to 5 months
Secondary outcomes (6)
Blood pressure
Measured: Up to 5 months
Heart rate
Measured: Up to 5 months
Medication compliance questionnaire.
A questionnaire about medication compliance will be administered to patients so that they can self report compliance with medications and compliance with dialysis.
Measured: Up to 5 months
Measure change in Pain using the Numeric Rating Scale 11 (NRS11)
Measured by the Numeric Rating Scale 11. This scale ranges from 0 to 11. A score of 0 indicates no pain while a score of 11 indicates severe pain.
Measured: Up to 5 months
Participant Energy
A questionnaire about energy will be administered to patients so that they can rate their energy on a scale from 0 to 5. A score of 0 indicates no energy while a score of 5 indicates a great amount of energy.
Measured: Up to 5 months
Mood
A questionnaire about mood will be administered to patients so that they can rate their mood on a scale from 0 to 5. A score of 0 indicates poor mood while a score of 5 indicates a great mood.
Measured: Up to 5 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Apr 2019
- Study start8 Mar 2019
- Primary completion1 Jan 2020
- Study completion1 Jan 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for End Stage Renal DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Cluster-randomized clinical trial
- Masking
- None (open label)
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tulane University
- Sponsor type
- University, hospital or other
- Collaborators
- National Kidney Foundation, United States
- Responsible party
- Sponsor
- Investigators
- Angelina Dixon, MD, Principal investigator, Tulane University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03925168
- Sponsor's protocol ID
- 2017-866
- Status last verified
- Jan 2021
- First submitted
- 16 Apr 2019
- Last updated
- 15 Jan 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Jan 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Music Therapy and Dialysis: A Pilot Investigation Into the Effectiveness of Patient-Selected Music Interventions on Physiological, Psychological, and Quality-of-Life Outcomes
- ClinicalTrials.gov ID
- NCT03925168
- Acronym / sponsor ID
- 2017-866
- Conditions
- End Stage Renal Disease, Depression, Anxiety, Major Depressive Disorder, Generalized Anxiety Disorder, Compliance, Patient
- Keywords
- end stage kidney disease, depression, major depressive disorder, anxiety, generalized anxiety disorder, music therapy, dialysis, quality of life
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 50 participants (actual)
- Lead sponsor
- Tulane UniversityUniversity, hospital or other
- Collaborators
- National Kidney Foundation, United States
- Study start
- 8 Mar 2019 (actual)
- Primary completion
- 1 Jan 2020 (actual)
- Study completion
- 1 Jan 2020 (actual)
- First posted
- 24 Apr 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to determine the effect of music therapy during dialysis on:
depression, anxiety, quality of life, blood pressure, heart rate, medication compliance, compliance with dialysis treatment, number of hospitalizations, pain level, and energy level.
Detailed description
This study will be a cluster-randomized clinical trial. In order to limit contamination bias, dialysis sessions at each site will be randomized to the experimental group or the wait-list control group. For example, patients receiving MWF first-session dialysis may be randomized to the experimental group while patients receiving TTS second-session dialysis may be randomized to the control group. Due to this randomization scheme, patients will be able to receive individualized music therapy while sitting in an open dialysis unit. The subject population includes English-speaking, adult (21+) hemodialysis patients who receive dialysis at the one of the two outpatient dialysis centers included in this study. Subjects will be excluded if they do not speak English or if they are deaf as these patient populations would not be likely to benefit from music therapy administered in English. Up to 100 patients will be enrolled in this study.
Patients receiving dialysis at DCI, Inc, who consent to participate and are randomized to the experimental group will receive 30-minute music therapy sessions over the course of several months. Music therapy will be administered by certified music therapists and music therapy students according to the Eyre (2008) decision tree model. According to this model, the patient chooses his or her preferred musical intervention at the beginning of each session. Choices include: sing songs, compose a song, listen to songs, play instruments, have an imagery experience, listen to music, improvise, and use music for relaxation. If the patient is unwilling or unable to make a decision, then the music therapist will choose an intervention based on the patient's perceived needs. For example, if the perceived need is expression of emotions, then the music therapist may suggest song composition, song choice, song singing, or improvisation. The music therapist will continue to assess the client's perceived needs based on their physical, verbal, and emotional responses to the chosen musical interventions, and the therapist will adjust their musical interventions accordingly (the complete Eyre Decision Tree Model is attached). The instruments utilized in music therapy will include a classic guitar, gato box (a small, drum-like instrument), and a 3-piece egg shaker set. All of these instruments can be played loudly enough to provide music therapy to the patient but softly enough as to not disturb the adjacent patients in the dialysis unit. In fact, these instruments are frequently used to provide music therapy to patients in open neonatal intensive care units.
The primary variables in this study include depression, anxiety, and quality of life. The median time to recovery for a major depressive episode is 20 weeks; therefore, patients randomized to the control group will receive music therapy for approximately 20 weeks. Depression will be measured using the Patient Health Questionnaire-9 (PHQ-9), anxiety will be measured using the Generalized Anxiety Disorder-7 (GAD-7), and quality of life will be measured using the Kidney Disease and Quality of Life (KDQOL™-36) questionnaire. These tools are self-administered questionnaires that will be provided by the music therapists to both the experimental and control groups once a month during the study. Any patient with a PHQ-9 score greater than 10 (moderate depression) or a GAD-7 score greater than 10 (moderate anxiety) will additionally be given resources for available mental health providers in the area. While these tools are validated to be utilized every two weeks, they will be utilized every month during this study to limit testing fatigue. In addition, the PHQ-9, GAD-7, and KDQOL™-36 will be administered 30, 60, and 90 days after the experimental group receives their last music therapy session to both the experimental and control groups to assess for recurrent episodes. Among patients with major depressive disorder, recurrent episodes occur in approximately 50 percent. The risk of reoccurrence appears to be greatest in the first few months after cessation of depressive therapy.
The secondary variables in this study include blood pressure, heart rate, medication compliance, compliance with dialysis treatment, number of hospitalizations, pain level, and energy level. The music therapists will record the heart rate (HR) and blood pressure (BP) of each patient at the beginning of dialysis as well as at the beginning and end of music therapy (or a 30-minute period during which music therapy would have been administered). These HRs and BPs will be recorded using nursing vitals. Prior to the start of each session, the music therapist will provide self-administered questionnaires that ask patients to rate their pain (utilizing the Numeric Rating Scale [NRS-11]), mood, anxiety, and energy level. The patients will rate their pain, mood, anxiety, and energy level at the end of the session as well. The music therapist will record if the patient stayed for their entire treatment, or if they asked to stop dialysis early (the complete weekly and monthly data collection forms are attached). Music therapy sessions will be audio recorded using a condenser microphone and iPad Pro, and any subjective feedback from dialysis patients about music therapy sessions will be recorded as well.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Cluster-randomized clinical trial
| Arm | Type | Receives |
|---|---|---|
| Experimental | Experimental | Behavioral: Music therapyMusic therapy |
| Control | No intervention | –No music therapy |
Who may qualify
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- English-speaking, adult (21+) hemodialysis patients who receive dialysis at the one of the two outpatient dialysis centers
Key exclusion criteria (1 listed)
- do not speak English, deafness
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Music therapyMusic therapy will be administered according to the Eyre (2008) decision tree model. According to this model, the patient chooses his or her preferred musical intervention at the beginning of each session. Choices include: sing songs, compose a song, listen to songs, play instruments, have an imagery experience, listen to music, improvise, and use music for relaxation. | Behavioural | Experimental |
Primary outcome
Depression
Time frame: Until 90 days post study
Measured by Patient Health Questionnaire 9 (PHQ-9). The PHQ-9 measures depression symptoms. Scores range from 0 to 27. A score of 0 to 4 indicates no depression symptoms, 5 to 9 indicates mild symptoms, 10 to 14 indicates moderate symptoms, 15 to 19 indicates moderately severe symptoms, and 20 to 27 indicates severe symptoms.
Anxiety
Time frame: Until 90 days post study
Measured by Generalized Anxiety Disorder 7 patient screening tool (GAD-7). The GAD-7 measures anxiety symptoms. Scores range from 0 to 21. A score of 5 or higher indicates mild anxiety, 10 or higher indicates moderate anxiety, and 15 or higher indicates severe anxiety.
Measuring change in Quality of life using Kidney Disease and Quality of Life 36 patient screening tool (KDQOL36)
Time frame: Until 90 days post study
Measured by Kidney Disease and Quality of Life 36 patient screening tool. The KDQOL36 measures quality of life for kidney disease patients. Scores range from 36 to 172. Lower scores indicate greater quality of life. Appropriate scores vary by age.
Compliance with dialysis
Time frame: Up to 5 months
Self-reported
Number of hospitalizations
Time frame: Up to 5 months
Self-reported
6 secondary outcomes
Blood pressure
Time frame: Up to 5 months
Heart rate
Time frame: Up to 5 months
Medication compliance questionnaire.
Time frame: Up to 5 months
Measure change in Pain using the Numeric Rating Scale 11 (NRS11)
Time frame: Up to 5 months
Participant Energy
Time frame: Up to 5 months
Mood
Time frame: Up to 5 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jan 2021.
- Individual participant dataSharing planned: No
Related trials for End Stage Renal Disease
Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
Not yet recruiting
Hypothermic Kidney Machine Perfusion With Omnisol
End Stage Renal Disease (ESRD), Kidney Transplant
Recruiting
Guiding Optimal Blood Pressure Management in Peritoneal Dialysis Pilot Trial
End Stage Kidney Disease (ESKD), Hypertension (HTN)
RecruitingObservational study
Physical Impairments in Children With Chronic Renal Failure
Chronic Kidney Failure, Chronic Kidney Diseases
RecruitingPhase 1
A Study to Test the Safety of the Study Drug Fosmanogepix and How the Body Handles It in Adults With Severe Kidney Failure on Dialysis
End Stage Renal Disease on Dialysis, Adult
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Angelina Dixon, MD principal investigator
Tulane University
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Music therapy in people with End Stage Renal Disease and Depression, run by Tulane University at 3 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Depression (time frame: Until 90 days post study). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jan 2021.